PBAC's latest decision on Lanreotide: Recommended with restriction (2024). Considered for Changes to Community Access (CA) listings to allow initiation of treatment for acromegaly, functional carcinoid tumour, and non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET), previously only permitted for continuation of treatment.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
7
first 2015
Submissions
7
2015 → 2024
Eligible population
Adults with acromegaly (with persistent elevation of mean growth hormone >2.5 micrograms per litre after failure of other therapies), functional carcinoid tumour (with intractable symptoms despite antidiarrhoeal/antihistamine/antiserotonin agents), or non-functional GEP-NET (WHO grade 1 or 2, unresectable locally advanced or metastatic disease).
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
This is a Category 3 minor submission requesting changes to existing listings (removal of 'prior treatment' criterion for CA initiation). No new economic evaluation or ICER was required or provided.
ICER (historical)
$15k/QALY–$45k/QALY across 2 submissions (2016–2017) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2015: Not recommended · Restricted
Nov 2016: Recommended with restriction · Authority Required — ICER $105k/QALY